Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. AA
10. TECHM:IN

Go back to Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor

January 30, 2017 6:45 AM EST

Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158  Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT

WILMINGTON, Del. AND SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Incyte Corporation (NASDAQ: INCY) and Calithera... More